Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Nicholas Gilpin
Lsu Health Sciences Center, Department: Physiology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Glauser Life Sciences, Inc.
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Nicholas Gilpin is the principal investigator on the above referenced project sponsored by the NIH. The goal of this project is to create a genetic animal model that can be distributed and used by multiple investigators in various pre-clinical neuroscience fields where corticotropin-releasing factor-1 signaling has been implicated as a promising therapeutic target. As required by CM-35, Dr. Gilpin disclosed that he owns (b)(4) shares in Glauser Life Sciences, Inc. The current value of his shares is (b)(4). Glauser Life Sciences, Inc. is a company that is developing treatments for alcoholism, chemical dependency, and PTSD. Glauser Life Sciences, Inc. is not involved in this project.
Generation and validation of a CRFR1-cre transgenic rat to study alcohol dependence
Project Narrative Alcohol Use Disorder (AUD) costs the United States and the world millions of lives and billions of dollars annually, and is highly co-morbid with various other psychiatric disorders. Over the last 20 years, one neural system that has shown significant promise as a potential therapeutic target for AUD and co-morbid disorders is corticotropin-releasing factor (CRF), and especially CRF signaling through the CRF-1 receptor (CRFR1). Recent advances in neuroscience allow for the creation of sophisticated genetic animal models that allow experimenters to target specific neuronal populations and analyze their role in network dynamics and behavioral measures; here we propose to develop and validate a CRFR1:Cre rat for use in pre-clinical studies on the neurobiology of AUD and related psychiatric conditions.
Filed on November 16, 2018.
Tell us what you know about Nicholas Gilpin's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Nicholas Gilpin filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Nicholas Gilpin | Lsu Health Sciences Center | Conflict of Interest | Glauser Life Science, Inc. | $0 - $4,999 |
| Nicholas Gilpin | Lsu Health Sciences Center | Conflict of Interest | Glauser Life Sciences, Inc. | $0 - $4,999 |
| Nicholas Gilpin | Lsu Health Sciences Center | Conflict of Interest | Glauser Life Sciences, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.